ClinicalTrials.gg
CompletedNCT02955212Updated Sep 27, 2021Results posted

A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)

A Phase 3 interventional study of Upadacitinib and Placebo in Rheumatoid Arthritis (RA), sponsored by AbbVie. Completed at 43 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-27.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
338
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing upadacitinib in Arthritis, Rheumatoid — 3 open to participants now, 3 under way, none of them phase 3. upadacitinib · Arthritis, Rheumatoid.

Enrollment
8th of 19
338 · median 300
Started
2018
with 1 other
Phase 3
7 of 19
none open now
Registered
10th of 19
by date
Lead sponsor
13 of 19
AbbVie

Among the 19 studies testing upadacitinib in Arthritis, Rheumatoid, this one is the 8th largest by enrollment, is one of 2 that started in 2018, is one of 7 in phase 3, and was the 10th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 19 studies testing upadacitinib in Arthritis, Rheumatoid are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About upadacitinib

upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing upadacitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The study objectives of Period 1 of this study were to compare the efficacy, safety, and tolerability of upadacitinib versus placebo for the treatment of signs and symptoms of subjects from China and selected countries including Brazil and South Korea with moderately to severely active rheumatoid arthritis (RA) who are on a stable dose of csDMARDs and have an inadequate response to csDMARDs.

The study objective of Period 2 is to evaluate the long-term safety, tolerability, and efficacy of upadacitinib in subjects with RA who have completed Period 1.

Read the detailed description

This is a Phase 3 multicenter study that includes two periods. Period 1 is a 12-week, randomized, double-blind, parallel-group, placebo-controlled period designed to compare the safety and efficacy of upadacitinib versus placebo for the treatment of signs and symptoms of participants with moderately to severely active RA who are on a stable dose of csDMARDs and have an inadequate response to csDMARDs. Period 2 is an open label 52 week extension period to evaluate the long-term safety, tolerability, and efficacy of upadacitinib in participants with RA who have completed Period 1.

03

Conditions studied

  • Rheumatoid Arthritis (RA)

Keywords

  • Rheumatoid Arthritis
  • Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)
  • ABT-494
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of RA for ≥ 3 months who also fulfill the 2010 American College of Rheumatology (ACR)/ European League Against Rheumatism (EULAR) classification criteria for RA.
  • Participants have been receiving csDMARD therapy ≥ 3 months and on a stable dose for ≥ 4 weeks prior to the first dose of study drug.

    1. Participants must have failed (lack of efficacy) at least one of the following: methotrexate (MTX), sulfasalazine, or leflunomide.
    2. The following csDMARDs are allowed: oral or parenteral MTX, sulfasalazine, hydroxychloroquine, chloroquine, and leflunomide.
    3. A combination of up to two background csDMARDs is allowed except the combination of MTX and leflunomide.
  • Participant meets both of the following disease activity criteria:

    1. ≥ 6 swollen joints (based on 66 joint counts) and ≥ 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits; and
    2. High-sensitivity C-Reactive Protein (hsCRP) ≥ 3 mg/L at Screening
  • Participants with prior exposure to at most one biological disease-modifying anti-rheumatic drugs (bDMARD) may be enrolled (up to 20% of total number of subjects). Specifically, prior to enrollment:

    1. Participants with limited exposure to bDMARD (\< 3 months) OR
    2. Participants who are responding to a bDMARD therapy but had to discontinue due to intolerability (regardless of treatment duration).
  • Participants must have discontinued bDMARD therapy prior to the first dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, and filgotinib).
  • Participants who are considered inadequate responders (lack of efficacy) to bDMARD therapy as defined by the Investigator.
  • History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than RA (including but not limited to gout, systemic lupus erythematosus, psoriatic arthritis, axial spondyloarthritis including ankylosing spondylitis and non-radiographic axial spondyloarthritis, reactive arthritis, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, fibromyalgia [currently with active symptoms]. Current diagnosis of secondary Sjogren's Syndrome is permitted.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
338 participants (actual)

Study arms

  • Placebo comparator
    Placebo / Upadacitinib 15 mg

    Participants randomized to receive placebo once daily for 12 weeks in Period 1 followed by upadacitinib 15 mg once daily for up to 52 weeks in Period 2.

    Drug: Upadacitinib · Drug: Placebo

  • Experimental
    Upadacitinib 15 mg

    Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1 and up to an additional 52 weeks in Period 2.

    Drug: Upadacitinib

Interventions

  • Tablets for oral administration

    Also known as: ABT-494, RINVOQ™

  • DrugPlacebo

    Tablets for oral administration

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change From Baseline in Disease Activity Score Based on CRP (DAS28 [CRP]) at Week 12

    The DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to 10, where higher scores indicate more disease activity. A negative change from Baseline in DAS28 (CRP) indicates improvement in disease activity.

    Time frame: Baseline and Week 12

  2. Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.

    Time frame: Baseline and Week 12

  3. Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12

    The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.

    Time frame: Baseline and Week 12

  4. Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28 (CRP) at Week 12

    Low disease activity based on DAS28 (CRP) is defined a DAS28 (CRP) score of ≤ 3.2. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to 10, where higher scores indicate more disease activity. A DAS28 score less than or equal to 3.2 indicates low disease activity.

    Time frame: Week 12

  5. Percentage of Participants Achieving Clinical Remission Based on DAS28 (CRP) at Week 12

    Clinical remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) score of less than 2.6. DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to 10, where higher scores indicate more disease activity.

    Time frame: Week 12

  6. Percentage of Participants Achieving Low Disease Activity Based on Clinical Disease Activity Index (CDAI) at Week 12

    Low disease activity based on CDAI is defined as a CDAI score ≤ 10. CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 76 with higher scores indicating higher disease activity.

    Time frame: Week 12

  7. Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 12

  8. Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 12

  9. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 1

07

Results

Posted Aug 6, 2020

Participant flow

Participants were enrolled at 37 sites in Brazil, China, and South Korea. The study consisted of a 12-week placebo-controlled, double-blind period (Period 1), and an open-label 52-week extension period (Period 2).

Period 1: Double-blind Treatment Period
Participant flow — Period 1: Double-blind Treatment Period
MilestonePlacebo / Upadacitinib 15 mgUpadacitinib 15 mg / Upadacitinib 15 mg
Started169169
Completed153157
Not completed1612
Withdrew: Adverse event47
Withdrew: Withdrawal by subject83
Withdrew: Lost to follow-up10
Withdrew: Other32
Period 2: Open-label Extension
Participant flow — Period 2: Open-label Extension
MilestonePlacebo / Upadacitinib 15 mgUpadacitinib 15 mg / Upadacitinib 15 mg
Started153157
Completed136139
Not completed1718
Withdrew: Adverse event117
Withdrew: Withdrawal by subject14
Withdrew: Lack of efficacy32
Withdrew: Covid-19 logistical restrictions01
Withdrew: Other24

Outcome measures

PrimaryPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
percentage of participantsPlaceboUpadacitinib 15 mg
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1231.4 (24.4 to 38.4)71.6 (64.8 to 78.4)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 · Response rate difference: 40.2 · 95% CI 30.5 to 50.0Response Rate Difference = Upadacitinib - Placebo
SecondaryChange From Baseline in Disease Activity Score Based on CRP (DAS28 [CRP]) at Week 12

The DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to 10, where higher scores indicate more disease activity. A negative change from Baseline in DAS28 (CRP) indicates improvement in disease activity.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Disease Activity Score Based on CRP (DAS28 [CRP]) at Week 12
units on a scalePlaceboUpadacitinib 15 mg
Change From Baseline in Disease Activity Score Based on CRP (DAS28 [CRP]) at Week 12-0.95 (-1.16 to -0.74)-2.56 (-2.76 to -2.36)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · ANCOVA · p = <0.001 · Least squares (ls) mean difference: -1.61 · 95% CI -1.86 to -1.36LS Mean Difference = Upadacitinib - Placebo
SecondaryChange From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12
units on a scalePlaceboUpadacitinib 15 mg
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12-0.18 (-0.28 to -0.09)-0.62 (-0.71 to -0.54)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · ANCOVA · p = <0.001 · Ls mean difference: -0.44 · 95% CI -0.55 to -0.33LS Mean Difference = Upadacitinib - Placebo
SecondaryChange From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12

The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12
units on a scalePlaceboUpadacitinib 15 mg
Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 123.36 (2.25 to 4.48)8.93 (7.80 to 10.07)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Mixed Effect Model Repeat Measurement · p = <0.001 · Ls mean difference: 5.57 · 95% CI 4.13 to 7.01LS Mean Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28 (CRP) at Week 12

Low disease activity based on DAS28 (CRP) is defined a DAS28 (CRP) score of ≤ 3.2. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to 10, where higher scores indicate more disease activity. A DAS28 score less than or equal to 3.2 indicates low disease activity.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28 (CRP) at Week 12
percentage of participantsPlaceboUpadacitinib 15 mg
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28 (CRP) at Week 1213.6 (8.4 to 18.8)46.2 (38.6 to 53.7)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 · Response rate difference: 32.5 · 95% CI 23.4 to 41.7Response Rate Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants Achieving Clinical Remission Based on DAS28 (CRP) at Week 12

Clinical remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) score of less than 2.6. DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to 10, where higher scores indicate more disease activity.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Remission Based on DAS28 (CRP) at Week 12
percentage of participantsPlaceboUpadacitinib 15 mg
Percentage of Participants Achieving Clinical Remission Based on DAS28 (CRP) at Week 125.3 (1.9 to 8.7)29.6 (22.7 to 36.5)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 · Response rate difference: 24.3 · 24.3% CI 16.6 to 31.9Response Rate Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants Achieving Low Disease Activity Based on Clinical Disease Activity Index (CDAI) at Week 12

Low disease activity based on CDAI is defined as a CDAI score ≤ 10. CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 76 with higher scores indicating higher disease activity.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Low Disease Activity Based on Clinical Disease Activity Index (CDAI) at Week 12
percentage of participantsPlaceboUpadacitinib 15 mg
Percentage of Participants Achieving Low Disease Activity Based on Clinical Disease Activity Index (CDAI) at Week 1211.2 (6.5 to 16.0)35.5 (28.3 to 42.7)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 · Response rate difference: 24.3 · 95% CI 15.6 to 32.9Response Rate Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12
percentage of participantsPlaceboUpadacitinib 15 mg
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 128.3 (4.1 to 12.4)40.8 (33.4 to 48.2)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 · Response rate difference: 32.5 · 95% CI 24.0 to 41.0Response Rate Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12
percentage of participantsPlaceboUpadacitinib 15 mg
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 123.6 (0.8 to 6.3)21.3 (15.1 to 27.5)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 · Response rate difference: 17.8 · 95% CI 11.0 to 24.5Response Rate Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 1
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1
percentage of participantsPlaceboUpadacitinib 15 mg
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 15.9 (2.4 to 9.5)25.4 (18.9 to 32.0)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 · Response rate difference: 19.5 · 95% CI 12.1 to 27.0Response Rate Difference = Upadacitinib - Placebo

Adverse events

Collected over Period 1: From the first dose of study drug up to Week 12 or up to 30 days after last dose for participants who discontinued study drug prior to Week 12. Period 2: From Week 12 to 30 days after last dose; up to 56 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period 1: Placebo0/169 (0%)5/169 (3%)13/169 (7.7%)
Period 1: Upadacitinib 15 mg0/169 (0%)12/169 (7.1%)25/169 (14.8%)
Period 1+2: Upadacitinib 15 mg0/322 (0%)55/322 (17.1%)198/322 (61.5%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
EventPeriod 1: PlaceboPeriod 1: Upadacitinib 15 mgPeriod 1+2: Upadacitinib 15 mg
PNEUMONIAInfections and infestations1/1693/1698/322
HERPES ZOSTERInfections and infestations0/1691/1694/322
TENDON RUPTUREInjury, poisoning and procedural complications0/1692/1692/322
CHOLELITHIASISHepatobiliary disorders0/1690/1693/322
APPENDICITISInfections and infestations0/1690/1692/322
POSTOPERATIVE WOUND INFECTIONInfections and infestations0/1690/1692/322
ANKLE FRACTUREInjury, poisoning and procedural complications0/1690/1692/322
DRUG-INDUCED LIVER INJURYHepatobiliary disorders1/1690/1690/322
ANAPHYLACTIC REACTIONImmune system disorders0/1691/1690/322
MENISCUS INJURYInjury, poisoning and procedural complications0/1691/1691/322
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPeriod 1: PlaceboPeriod 1: Upadacitinib 15 mgPeriod 1+2: Upadacitinib 15 mg
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations11/16916/16965/322
ALANINE AMINOTRANSFERASE INCREASEDInvestigations2/1699/16930/322
BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations0/1690/16929/322
HEPATIC FUNCTION ABNORMALHepatobiliary disorders0/1690/16927/322
ANAEMIABlood and lymphatic system disorders0/1690/16926/322
LEUKOPENIABlood and lymphatic system disorders0/1690/16926/322
NASOPHARYNGITISInfections and infestations0/1690/16924/322
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations0/1690/16924/322
HERPES ZOSTERInfections and infestations0/1690/16923/322
WEIGHT INCREASEDInvestigations0/1690/16923/322

Baseline characteristics

The Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboUpadacitinib 15 mgTotal
Mean51.7 ± 11.3951.7 ± 10.6351.7 ± 11.00
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboUpadacitinib 15 mgTotal
Female139135274
Male303464
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboUpadacitinib 15 mgTotal
Hispanic or Latino212445
Not Hispanic or Latino148145293
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboUpadacitinib 15 mgTotal
White191938
Black or African American336
American Indian/Alaska Native000
Native Hawaiian or other Pacific Islander000
Asian142141283
Multiple5611
Enrollment by Country
Enrollment by Country(Participants)PlaceboUpadacitinib 15 mgTotal
China114114228
South Korea292958
Brazil262652
Duration Since Rheumatoid Arthritis (RA) Diagnosis
Duration Since Rheumatoid Arthritis (RA) Diagnosis(years)PlaceboUpadacitinib 15 mgTotal
Mean7.5 ± 7.557.2 ± 7.167.3 ± 7.35
Tender Joint Count
Tender Joint Count(joints)PlaceboUpadacitinib 15 mgTotal
Mean23.0 ± 14.4521.5 ± 14.8422.3 ± 14.64
Swollen Joint Count
Swollen Joint Count(joints)PlaceboUpadacitinib 15 mgTotal
Mean11.9 ± 6.0011.9 ± 6.8911.9 ± 6.45

5 further baseline measures are reported on the registry.

08

Study locations

43 sites
  • Ceti - Centro de Estudos Em Terapias Inovadoras Ltda /Id# 152964
    Curitiba, Parana 80030-110, Brazil
  • Parana Medical Research Center /ID# 153507
    Maringa, Parana 87015-000, Brazil
  • LMK Sevicos Medicos S/S /ID# 152963
    Porto Alegre, Rio Grande Do Sul 90480-000, Brazil
  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 152961
    Sao Jose Do Rio Preto, Sao Paulo 15090-000, Brazil
  • CEPIC - Centro Paulista de Investigação Clínica e Serviços Médicos Ltda /ID# 152966
    São Paulo, Sao Paulo 04266-010, Brazil
  • 1st Aff Hosp of Bengbu Med Col /ID# 162161
    Bengbu, Anhui 233099, China
  • Anhui Provincial Hospital /ID# 161117
    Hefei, Anhui 230001, China
  • Zhongshan Hosp. of Fudan Uni. /ID# 161108
    Shanghai, Anhui 200032, China
  • The 1st Aff Hosp Xiamen Univ /ID# 162154
    Xiamen, Fujian 361003, China
  • Zhuzhou Central Hospital /ID# 162153
    Zhuzhou, Hunan 412007, China
  • The First Affiliated Hospital /ID# 163747
    Baotou, Inner Mongolia 014016, China
  • The First People's Hospital /ID# 168462
    Changzhou, Jiangsu 213004, China
  • The First People's Hospital of Jiujiang /ID# 168461
    Jiujiang, Jiangxi 332000, China
  • The First Hosp of Jilin Univ /ID# 161116
    Changchun, Jilin 130021, China
  • Jining No.1 People's Hospital /ID# 162158
    Jining, Shandong 272001, China
  • Shanghai Changhai Hospital /ID# 161123
    Shanghai, Shanghai 200433, China
  • West China Hospital /ID# 161119
    Chengdu, Sichuan 610041, China
  • Xuanwu Hosp Capital Med Univ /ID# 161118
    Beijing, 100053, China
  • Peking Union Med College Hosp /ID# 161107
    Beijing, 100730, China
  • The Second Xiangya Hospital of Central South University /ID# 162152
    Changsha, 410000, China
  • First Affiliated Hospital of Kunming Medical University /ID# 164637
    Kunming, 650032, China
  • Jiangsu Province Hospital /ID# 161122
    Nanjing, 210029, China
  • Pingxiang People's Hospital /ID# 162151
    Pingxiang, 337055, China
  • 1st Aff Hosp of Shantou Univ /ID# 162165
    Shantou Guangdong, 515041, China
  • The Second Hospital of Shanxi /ID# 162164
    Taiyuan, 030001, China
  • Tianjin Med Univ General Hosp /ID# 162155
    Tianjin, 300052, China
  • People's Hospital of Xinjiang /ID# 162157
    Urumqi, 830001, China
  • First Affiliated Hospital of Xi'an Jiaotong University /ID# 162150
    Xi'an, 710061, China
  • SoonChunHyang University CheonAn Hospital /ID# 209078
    Cheonan-si, Chungcheongnamdo 31151, Korea, Republic of
  • Kyungpook National Univ Hosp /ID# 166919
    Daegu, Daegu Gwang Yeogsi 41944, Korea, Republic of
  • Chungnam National University Hospital /ID# 167727
    Jung-gu, Daejeon Gwang Yeogsi 35015, Korea, Republic of
  • Ajou University Hospital /ID# 163912
    Suwon-si, Gyeonggido 16499, Korea, Republic of
  • St. Vincent's Hospital /ID# 166918
    Suwon, Gyeonggido 16247, Korea, Republic of
  • Inha University Hospital /ID# 163910
    Jung-gu, Incheon Gwang Yeogsi 22332, Korea, Republic of
  • Chonnam National University Hospital /ID# 167726
    Gwangju, Jeonranamdo 61469, Korea, Republic of
  • Kyung Hee University Medical Center /ID# 163908
    Dongdaemun-gu, Seoul Teugbyeolsi 02447, Korea, Republic of
  • SMG-SNU Boramae Medical Center /ID# 163911
    Dongjak-gu, Seoul Teugbyeolsi 07061, Korea, Republic of
  • Yonsei University Health System, Severance Hospital /ID# 168421
    Seodaemun-gu, Seoul Teugbyeolsi 03722, Korea, Republic of
  • Hanyang University Seoul Hospi /ID# 163913
    Seongdong-gu, Seoul Teugbyeolsi 04763, Korea, Republic of
  • Konkuk University Medical Ctr /ID# 206148
    Seoul, Seoul Teugbyeolsi 05030, Korea, Republic of
  • The Catholic University of Korea, Yeouido St. Mary's Hospital /ID# 204224
    Seoul, Seoul Teugbyeolsi 07345, Korea, Republic of
  • Asan Medical Center /ID# 163909
    Seoul, 05505, Korea, Republic of
  • Chung-Ang University Hostipal /ID# 209076
    Seoul, 06973, Korea, Republic of
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Aug 2019, 19 months.

Results were first posted in Aug 2020, 11 months after primary completion.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 19 months is below that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2016
First posted
Nov 4, 2016
StartActual
Jan 3, 2018
Primary completionActual
Aug 14, 2019
CompletionActual
Sep 3, 2020
Results first posted
Aug 6, 2020
Last update
Sep 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02955212
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 4, 2016
Start date
Jan 3, 2018
Primary completion
Aug 14, 2019
Completion
Sep 3, 2020
Results posted
Aug 6, 2020
Last update
Sep 27, 2021

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion